Biotech’s sweet home: Alabama?
Is all publicity good publicity? Alabama biotech may soon find out. The local industry struggled to gain visibility and interest from investors on either coast — until the rise and fall of Roy Moore put it on the map.
Spark Therapeutics’ new FDA approval shows gene therapies are officially on fire
Spark Therapeutics claimed a number of firsts on Tuesday, with the historic approval of its one-time gene therapy, Luxturna, for the treatment of adults and children with an inherited retinal disease.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Billion-dollar cancer detection startup Grail names new CEO with commercial chops
After the surprise departure of its founding CEO in August, Illumina spin-out Grail has named Roche/Genentech’s Global Head of Clinical Operations Jennifer Cook as its new leader.
Tempus unveils a standalone tool for structuring clinical data at scale
Why do some patients respond to immuno-oncology drugs when others don’t? Tempus developed a tool to aggregate the phenotypic, therapeutic, and outcome and response data to help physicians answer this question.
Roche’s lung cancer data look good, so why didn’t the market react to clinical trial results?
Roche’s anti-PD-L1 drug Tecentriq took a step closer to regulatory approval as a combination drug for untreated non-small cell lung cancer patients. So why weren’t investors impressed?
Myriad’s riskScore test for breast cancer risk adds a second layer of precision
Just 10 percent of women with a family history of breast cancer test positive for one of the 11 genes directly associated with disease risk. Myriad’s new riskScore assessment caters to the other 90 percent.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
AI and RNA splicing: Is Envisagenics’ $2.35M seed round a sign of what’s to come?
With its AI platform, New York City headquarters, and diverse investor base, Envisagenics is hitting on some major trends in biotech development.
With $44M fundraise, could Fractyl make bariatric surgery the penicillin of our generation?
Fractyl Laboratories has raised a $44 million Series D financing round to build upon a chance discovery that bariatric surgery can resolve Type 2 diabetes in a subset of patients — independent of any weight loss.
HHS nominee Alex Azar talks drug pricing and ACA politics
As HHS secretary, Alex Azar would oversee a trillion-dollar budget, over 90,000 employees, and a healthcare system that is ground-zero for heated bipartisan politics. So where does Trump’s new nominee stand on the major issues?
Stepping stones to a new era in gene editing?
After 22 years, gene editing pioneer Sangamo Therapeutics is taking the plunge with three new in vivo gene editing clinical trials. If successful, the studies could serve as a template for myriad other genetic disorders.
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Forget what drugs were approved. What drugs performed well?
The second annual Trinity Drug Index was published this week, sharing some valuable lessons on the success and failure of the 41 drugs approved back in 2014.
Syapse raises a $30M Series D round to scale its precision medicine program
“Life science companies recognize that they need to be able to work more closely with providers,” said Syapse CEO Ken Tarkoff.
Arcus Biosciences closes $107M Series C round as industry hunts for blockbuster immunotherapy combinations
New research by the Cancer Research Institute puts the number of industry-wide combination trials at 1,105.
How can biotech companies avoid losing public’s trust?
Are people wary of genomics and biotech companies, or just what a clinical study might reveal? Two case studies of consent rates for newborn sequencing might shed light on the answer.
Can a math model help predict an immune response to cancer?
A new Nature paper has described a first-of-its-kind mathematical model for predicting how a cancer patient will benefit from checkpoint inhibitors, a class of drugs that includes Merck’s Keytruda and Bristol Myers-Squibb’s Opdivo.